EGRX News and Press, Eagle Pharmaceuticals Inc. From 09/24/20

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that its Board of Directors has approved a $25 million accelerated share repurchase (“ASR”) transaction with JPMorgan Chase Bank, National Association (“...

Eagle Pharmaceuticals' (EGRX) marketing partner, SymBio Pharmaceuticals has received regulatory approval for TREAKISYM ready-to-dilute ((RTD)) (250 ml) liquid formulation from the Pharmaceuticals and Medical Devices Agency ((PMDA)) in Japan.As a result, the company will receive a $5M mileston...

- Eagle to receive $5 million milestone payment - - RTD and Rapid Infusion (“RI”) formulations could generate $10 million - $25 million annually for Eagle - Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today ...

Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (NASDAQ: EGRX) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at two upcoming conferences in September. At the Morgan Stanley 18 th Annu...

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that preclinical research on dantrolene sodium was published today in the peer-reviewed Journal of Alzheimer’s Disease . 1 The article reported results from an academic...

For  Q2 , Eagle Pharmaceuticals ( EGRX -7.7% ) revenue of $41.94M (-26.0% Y/Y)  missing consensus by $0.29M;  indicating lower product sales of BELRAPZO and BENDEKA, partially offset by higher product sales of RYANODEX. More news on: Eagle Pharmaceuticals, Inc., Hea...

Image source: The Motley Fool. Eagle Pharmaceuticals Inc   (NASDAQ: EGRX) Q2 2020 Earnings Call Aug 10, 2020 , 8:30 a.m. ET Operator Continue reading

Eagle Pharmaceuticals, Inc. (EGRX) Q2 2020 Earnings Conference Call August 10, 2020 8:30 a.m. ET Company Participants Lisa Wilson - IR Scott Tarriff - CEO Pete Meyers - CFO David Pernock - President and COO Conference Call Participants Randall Stanicky - RBC Capital Marke...

Eagle Pharmaceuticals (NASDAQ: EGRX ) : Q2 Non-GAAP EPS of $0.57 beats by $0.34 ; GAAP EPS of -$0.02 beats by $0.30 . More news on: Eagle Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

-- Q2 2020 net loss was ($0.02) per basic and diluted share and adjusted non-GAAP net income was $0.59 per basic and $0.57 per diluted share -- -- Anticipate launch of vasopressin, maintaining our 180-day market exclusivity -- -- CMS establishes unique J-code for PEMFEXY™ (pem...